Abstract:22201 Background: We explored the clinical value of circulating tumor cells (CTCs) in prognosis and the assessment of treatment effects for patients with lung cancer. Methods: In a prospective, single center and small sampling study, we tested the levels of CTC at baseline in 100 patients with emerging or recurring lung cancer and followed up 60 with CTC numbers after each cycle of chemotherapy. We then did correlation analysis between CTC variation and treatment-response evaluation based on RECIST criteria. We used AVIVABio Cancer Cell Isolating Technology, an immunomagnetic beads-based rare cell enrichment system using leucocyte depletion mechanism, to count the identified CK+/EGFR+/CD45- CTCs in 7.5ml venous blood of the lung cancer patients under fluroscence microscopy. Results: 100 blood samples were collected from newly diagnosed or recurrent lung cancer patients who had been treatment-naive for at least 2 months before hospitalization. Benign respiratory diseases and tuberculosis and healthy control samples were collected, 20 for each group, during the same study period. The AVIVABio Technology is easy to manage and repeatable with a sentivity of 92.5%and specificity of 68.4% in lung cancer patients. The patients with TNM stage IIIA or below had a CTC positive rate of 31.8%(7/22), and those of IIIB or above had a statistically high rate of 87.2%(68/78) (P<0.001). 60 patients were followed up with CTC after each cycle of chemotherapy. After one chemo cycle, 93.3%(56/60) patients' CTC were negative with the remaining persistent or turning positive. Correlation analysis showed the variation of CTC was coincident with RECIST criteria by CT scan after two chemo cycles. Conclusions: The above-mentioned method is highly sensitive and specific in detecting CTC of the patients with advanced lung cancer. The initial level of CTC identified using this method has prognostic value. The variation of CTC in the course of chemotherapy might be a useful predictor of the chemo-response or disease-progression. Correlation between CTC levels and Clinical Factors Factors Sub-Group Number of Sampled Patients Number of CTC Positive Patients CTC Positive Rate (%) P value TNM staging Operatable 22 7 31.8 < 0.001 Unoperatable 78 68 87.2 Pathology Adenocarcinoma 69 57 82.6 < 0.05 Squamous Carcimona 16 10 62.5 not Small Cell 15 8 53.3 not Due to AJCC TNM Staging System: below IIIA-operatable; above IIIB-unoperatable No significant financial relationships to disclose.

CD47 Expression in Circulating Tumor Cells and Circulating Tumor Microemboli from Non-Small Cell Lung Cancer Patients Is a Poor Prognosis Factor

Tumor CD47 Expression and a High M2/M1 Ratio of Tumor-Associated Macrophages As an Adverse Prognostic Factor in Resected Stage Ⅲa Non-Small Cell Lung Cancer.

P2.03b-092 Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy: Topic: Biomarkers

Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

P1.07-031 Clinical Evaluation of Folate Receptor-Positive Circulating Tumor Cells Detection in Patients with Small Cell Lung Cancer: Topic: Molecular Changes

Role of CD47 in tumor immunity: a potential target for combination therapy

Assessment of PD-L1 and CD47 Expression Together with Tumor-Associated TILs in Resectable Early Stage NSCLC

Folate Receptor-Positive Circulating Tumor Cells As a Predictive Biomarker for the Efficacy of First-Line Pemetrexed-Based Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Predictive and Prognostic Value of Folate Receptor-Positive Circulating Tumor Cells in Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

Prognostic implications of combined high expression of CD47 and MCT1 in breast cancer: a retrospective study during a 10-year period

CD45+CD326+ Cells Are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients

Prognostic Importance of Circulating Tumor Cells in Non-Small Cell Lung Cancer: A Prospective Study

The Clinical Values of Circulating Tumor Cells and T Lymphocyte Subsets in Predicting a Prognosis of Lung Cancer

Circulating Tumor Cells (CTC): Assessment of Treatment Efficacy in Metastatic Breast Cancer (MBC)

CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer

Dynamic Changes of Circulating Tumor Cells During Chemotherapy As a Prognostic Factor in Patients with Advanced Lung Cancer.

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

Circulating Tumor Cells (CTC) As a Prognostic and Predictive Factor in Lung Cancer Patients–a Pilot Study in PUMCH

Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients

Influence of CD47 on CD8 + T-cell and tumor prognosis based on pan-cancer analysis.

Interstitial Tumor-Associated Macrophages Combined with Tumor-Derived Colony-Stimulating Factor-1 and Interleukin-6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer.